Motixafortide

N/A

Report date: 2026/05/07 20:00:36
NME

Base Information

Drug NameMotixafortide
Drug Alias NameAPHEXDA4F-Benzoyl-TN14003TN-14003TF-14016BL-8040 +[8] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionC-X-C motif chemokine receptor 4 antagonists
TargetsC-X-C motif chemokine receptor 4
Therapy Area/IndicationsMyeloproliferative DisordersMyelodysplastic SyndromesAnemia, Sickle Cell +[16] 
Global Approved IndicationsHematopoietic stem cell transplantation (HSCT)
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/09/08
Country/TerritoryCzechiaUnited StatesSlovakia +[14] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBiokineKyoto University
China Registration ClassN/A

Develop Information

Active CompaniesBiolinerx LtdAyrmid Pharma LtdAyrmid Ltd +[9] 
Inactive CompaniesBiokine Therapeutics Ltd
Active IndicationsMyeloproliferative DisordersMyelodysplastic SyndromesAnemia, Sickle Cell +[13] 
Inactive IndicationsAnemia, AplasticLymphoma, T-CellPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG